NCT05763459

A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects

A Phase 1 Study to Evaluate the Drug-Drug Interaction Between ABBV-CLS-7262, Rosuvastatin, and Digoxin Following Multiple Doses of ABBV-CLS-7262

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Calico Life Sciences LLC · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study follows an open-label, single arm design with two periods with rosuvastatin, digoxin and ABBV-CLS-7262

Detailed description

Period 1: One single dose of rosuvastatin and one single dose of digoxin on Day 1. Period 2: Multiple doses of ABBV-CLS-7262 once daily from Day 1 to Day 8. On Day 5, one single dose of rosuvastatin and one single dose of digoxin with the dose of ABBV-CLS-7262 on that day.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	ABBV-CLS-7262	Drug: ABBV-CLS-7262 Drug: Digoxin Drug: Rosuvastatin

Timeline

• Start date: 2023-03-24
• Primary completion: 2023-05-08
• Completion: 2023-06-02
• First posted: 2023-03-10
• Last updated: 2023-06-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study